Cell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Your Basket's Financial Footprint
Concise summary and investor key takeaways for the Cell & Gene Therapy Logistics basket.
- Large-cap dominance implies generally lower volatility and closer alignment with broad-market performance, reducing idiosyncratic risk.
- Suitable as a core long-term holding to provide stable sector exposure, not as a high-risk speculative position.
- Expect steady, long-term value creation rather than rapid, short-term gains; incremental upside likely, not guaranteed.
CYRX: $508.18M
BLFS: $1.33B
CCEL: $35.04M
- Other
About This Group of Stocks
Our Expert Thinking
We're focused on the companies behind the scenes making cell and gene therapy possible. Instead of betting on which treatments will succeed, we've selected the firms providing crucial infrastructure—from cryogenic storage to manufacturing components—that all therapies need regardless of clinical outcomes.
What You Need to Know
These stocks offer a different risk profile than traditional biotech investments. While they still operate in a fast-evolving sector, their services remain essential regardless of which specific therapies ultimately succeed, providing a more stable approach to capturing growth in advanced medicine.
Why These Stocks
Each company was selected because they provide irreplaceable services in the cell and gene therapy supply chain. As more advanced treatments receive regulatory approval, these firms face increasing demand for their specialized logistics, manufacturing capabilities, and quality control systems.
Why You'll Want to Watch These Stocks
The Cold Chain Craze
Cell and gene therapies need ultra-cold storage and transport to work. As more of these treatments get approved, the companies keeping them frozen become critical—an opportunity most investors are missing.
The Invisible Winners
While headline-grabbing biotech firms often face binary outcomes based on clinical trials, these behind-the-scenes companies earn revenue regardless of which therapies ultimately succeed—potentially offering smoother growth.
Riding The Approval Wave
With cell and gene therapy approvals accelerating, demand for specialized manufacturing and logistics is surging. These companies are positioned to benefit from this momentum as the field transforms from experimental to mainstream.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Mining Mega-Mergers: Could They Reshape Competition?
Global mining giants Rio Tinto and Glencore are in preliminary talks for a merger that could create the world's largest mining company. This move signals a trend of major consolidation in the sector, potentially creating opportunities for other mining companies and the equipment suppliers that support them.
U.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Gulf Coast Refiners (Venezuelan Crude) Opportunity
Global commodities trader Trafigura is resuming Venezuelan oil exports to the U.S. after a major political shift, creating a new supply stream for American markets. This development stands to benefit U.S. refiners and energy infrastructure companies that will process and transport the renewed crude flows.